Corxel Pharmaceuticals has received FDA clearance for a Phase II trial of CX11, an oral once-daily small molecule GLP-1 receptor agonist for obesity treatment, with enrollment expected to begin in Q2 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.